Research ArticleHIV

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge

See allHide authors and affiliations

Science Translational Medicine  06 Sep 2017:
Vol. 9, Issue 406, eaal1321
DOI: 10.1126/scitranslmed.aal1321

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Potently protective antibodies

HIV is thought to be an elusive virus, but there are multiple epitopes on HIV that can be targeted by neutralizing antibodies, such as the V2 loop of the envelope protein. Julg et al. reasoned that potent anti-V2 HIV antibodies given prophylactically could prevent infection from taking place. They tested this in nonhuman primates with a novel clade C SHIV strain and observed protection at very low concentrations of circulating neutralizing antibody, suggesting that passive immunization with these types of antibodies might be protective in people.